Research ExplorerPublicationsIntermediate Follow-up of Pediatric Patients With Hemolytic ...

Intermediate Follow-up of Pediatric Patients With Hemolytic Uremic Syndrome During the 2011 Outbreak Caused by E. coli O104:H4

Standard

Intermediate Follow-up of Pediatric Patients With Hemolytic Uremic Syndrome During the 2011 Outbreak Caused by E. coli O104:H4. / Loos, Sebastian; Aulbert, Wiebke; Hoppe, Bernd; Ahlenstiel-Grunow, Thurid; Kranz, Birgitta; Wahl, Charlotte; Staude, Hagen; Humberg, Alexander; Benz, Kerstin; Krause, Martin; Pohl, Martin; Liebau, Max Christoph; Schild, Raphael; Lemke, Johanna; Beringer, Ortraud; Müller, Dominik; Härtel, Christoph; Wigger, Marianne; Vester, Udo; Konrad, Martin; Haffner, Dieter; Pape, Lars; Oh, Jun; Kemper, Markus J.

In: CLIN INFECT DIS, Vol. 64, No. 12, 15.06.2017, p. 1637-1643.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Loos, S, Aulbert, W, Hoppe, B, Ahlenstiel-Grunow, T, Kranz, B, Wahl, C, Staude, H, Humberg, A, Benz, K, Krause, M, Pohl, M, Liebau, MC, Schild, R, Lemke, J, Beringer, O, Müller, D, Härtel, C, Wigger, M, Vester, U, Konrad, M, Haffner, D, Pape, L, Oh, J & Kemper, MJ 2017, 'Intermediate Follow-up of Pediatric Patients With Hemolytic Uremic Syndrome During the 2011 Outbreak Caused by E. coli O104:H4', CLIN INFECT DIS, vol. 64, no. 12, pp. 1637-1643. https://doi.org/10.1093/cid/cix218

APA

Loos, S., Aulbert, W., Hoppe, B., Ahlenstiel-Grunow, T., Kranz, B., Wahl, C., Staude, H., Humberg, A., Benz, K., Krause, M., Pohl, M., Liebau, M. C., Schild, R., Lemke, J., Beringer, O., Müller, D., Härtel, C., Wigger, M., Vester, U., ... Kemper, M. J. (2017). Intermediate Follow-up of Pediatric Patients With Hemolytic Uremic Syndrome During the 2011 Outbreak Caused by E. coli O104:H4. CLIN INFECT DIS, 64(12), 1637-1643. https://doi.org/10.1093/cid/cix218

Vancouver

Loos S, Aulbert W, Hoppe B, Ahlenstiel-Grunow T, Kranz B, Wahl C et al. Intermediate Follow-up of Pediatric Patients With Hemolytic Uremic Syndrome During the 2011 Outbreak Caused by E. coli O104:H4. CLIN INFECT DIS. 2017 Jun 15;64(12):1637-1643. https://doi.org/10.1093/cid/cix218

Bibtex

@article{4f2f58b2efc6435d984abb4f2aa76378,
title = "Intermediate Follow-up of Pediatric Patients With Hemolytic Uremic Syndrome During the 2011 Outbreak Caused by E. coli O104:H4",
abstract = "Background.: In 2011 Escherichia coli O104:H4 caused an outbreak with >800 cases of hemolytic uremic syndrome (HUS) in Germany, including 90 children. Data on the intermediate outcome in children after HUS due to E. coli O104:H4 have been lacking.Methods.: Follow-up data were gathered retrospectively from the medical records of patients who had been included in the German Pediatric HUS Registry during the 2011 outbreak.Results.: Seventy-two of the 89 (81%) patients were included after a median follow-up of 3.0 (0.9-4.7) years. Hypertension and proteinuria were present in 19% and 28% of these patients, respectively. Of 4 patients with chronic kidney disease (CKD) > stage 2 at short-term follow-up, 1 had a normalized estimated glomerular filtration rate, and 3 (4%) had persistent CKD > stage 2. In 1 of these patients, CKD improved from stage 4 to 3; 1 who had CKD stage 5 at presentation received kidney transplantation; and 1 patient required further hemodialysis during follow-up. One patient (1.4%) still had major neurological symptoms at the latest follow-up. Dialysis during the acute phase (P = .01), dialysis duration (P = .01), and the duration of oligo-/anuria (P = .005) were associated with the development of renal sequelae. Patients treated with eculizumab (n = 11) and/or plasmapheresis (n = 13) during the acute phase of HUS had comparable outcomes.Conclusions.: The overall outcome of pediatric patients after HUS due to E. coli O104:H4 was equivalent to previous reports on HUS due to other types of Shiga toxin-producing E. coli (STEC). Regular follow-up visits in patients are recommended after STEC-HUS.",
keywords = "Journal Article",
author = "Sebastian Loos and Wiebke Aulbert and Bernd Hoppe and Thurid Ahlenstiel-Grunow and Birgitta Kranz and Charlotte Wahl and Hagen Staude and Alexander Humberg and Kerstin Benz and Martin Krause and Martin Pohl and Liebau, {Max Christoph} and Raphael Schild and Johanna Lemke and Ortraud Beringer and Dominik M{\"u}ller and Christoph H{\"a}rtel and Marianne Wigger and Udo Vester and Martin Konrad and Dieter Haffner and Lars Pape and Jun Oh and Kemper, {Markus J}",
year = "2017",
month = jun,
day = "15",
doi = "10.1093/cid/cix218",
language = "English",
volume = "64",
pages = "1637--1643",
journal = "CLIN INFECT DIS",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "12",

}

RIS

TY - JOUR

T1 - Intermediate Follow-up of Pediatric Patients With Hemolytic Uremic Syndrome During the 2011 Outbreak Caused by E. coli O104:H4

AU - Loos, Sebastian

AU - Aulbert, Wiebke

AU - Hoppe, Bernd

AU - Ahlenstiel-Grunow, Thurid

AU - Kranz, Birgitta

AU - Wahl, Charlotte

AU - Staude, Hagen

AU - Humberg, Alexander

AU - Benz, Kerstin

AU - Krause, Martin

AU - Pohl, Martin

AU - Liebau, Max Christoph

AU - Schild, Raphael

AU - Lemke, Johanna

AU - Beringer, Ortraud

AU - Müller, Dominik

AU - Härtel, Christoph

AU - Wigger, Marianne

AU - Vester, Udo

AU - Konrad, Martin

AU - Haffner, Dieter

AU - Pape, Lars

AU - Oh, Jun

AU - Kemper, Markus J

PY - 2017/6/15

Y1 - 2017/6/15

N2 - Background.: In 2011 Escherichia coli O104:H4 caused an outbreak with >800 cases of hemolytic uremic syndrome (HUS) in Germany, including 90 children. Data on the intermediate outcome in children after HUS due to E. coli O104:H4 have been lacking.Methods.: Follow-up data were gathered retrospectively from the medical records of patients who had been included in the German Pediatric HUS Registry during the 2011 outbreak.Results.: Seventy-two of the 89 (81%) patients were included after a median follow-up of 3.0 (0.9-4.7) years. Hypertension and proteinuria were present in 19% and 28% of these patients, respectively. Of 4 patients with chronic kidney disease (CKD) > stage 2 at short-term follow-up, 1 had a normalized estimated glomerular filtration rate, and 3 (4%) had persistent CKD > stage 2. In 1 of these patients, CKD improved from stage 4 to 3; 1 who had CKD stage 5 at presentation received kidney transplantation; and 1 patient required further hemodialysis during follow-up. One patient (1.4%) still had major neurological symptoms at the latest follow-up. Dialysis during the acute phase (P = .01), dialysis duration (P = .01), and the duration of oligo-/anuria (P = .005) were associated with the development of renal sequelae. Patients treated with eculizumab (n = 11) and/or plasmapheresis (n = 13) during the acute phase of HUS had comparable outcomes.Conclusions.: The overall outcome of pediatric patients after HUS due to E. coli O104:H4 was equivalent to previous reports on HUS due to other types of Shiga toxin-producing E. coli (STEC). Regular follow-up visits in patients are recommended after STEC-HUS.

AB - Background.: In 2011 Escherichia coli O104:H4 caused an outbreak with >800 cases of hemolytic uremic syndrome (HUS) in Germany, including 90 children. Data on the intermediate outcome in children after HUS due to E. coli O104:H4 have been lacking.Methods.: Follow-up data were gathered retrospectively from the medical records of patients who had been included in the German Pediatric HUS Registry during the 2011 outbreak.Results.: Seventy-two of the 89 (81%) patients were included after a median follow-up of 3.0 (0.9-4.7) years. Hypertension and proteinuria were present in 19% and 28% of these patients, respectively. Of 4 patients with chronic kidney disease (CKD) > stage 2 at short-term follow-up, 1 had a normalized estimated glomerular filtration rate, and 3 (4%) had persistent CKD > stage 2. In 1 of these patients, CKD improved from stage 4 to 3; 1 who had CKD stage 5 at presentation received kidney transplantation; and 1 patient required further hemodialysis during follow-up. One patient (1.4%) still had major neurological symptoms at the latest follow-up. Dialysis during the acute phase (P = .01), dialysis duration (P = .01), and the duration of oligo-/anuria (P = .005) were associated with the development of renal sequelae. Patients treated with eculizumab (n = 11) and/or plasmapheresis (n = 13) during the acute phase of HUS had comparable outcomes.Conclusions.: The overall outcome of pediatric patients after HUS due to E. coli O104:H4 was equivalent to previous reports on HUS due to other types of Shiga toxin-producing E. coli (STEC). Regular follow-up visits in patients are recommended after STEC-HUS.

KW - Journal Article

U2 - 10.1093/cid/cix218

DO - 10.1093/cid/cix218

M3 - SCORING: Journal article

C2 - 28329394

VL - 64

SP - 1637

EP - 1643

JO - CLIN INFECT DIS

JF - CLIN INFECT DIS

SN - 1058-4838

IS - 12

ER -